The business model

in page functions

Through Gavi, the international community has established an innovative business model that not only finances the introduction of new vaccines in developing countries, but also reshapes the vaccine market 

GAVI's business model

Visit Gavi's Secretariat headquarters in Geneva, Switzerland and there is an unassuming air about the building and its day-to-day business.

Approximately 125 staff oversee Gavi's programmes and policies, review developing country applications, disburse billions of dollars of donor funds to purchase vaccines for immunisation programmes and monitor the results.

Like no other existing actor

In reality, Gavi’s financial support for delivering new vaccines to developing countries works like no other existing actor in international health. It not only pays for the vaccines, but also spurs their development and expanded production.

By pooling the demand from developing countries for new vaccines and providing long-term, predictable financing to meet this demand, the Vaccine Alliance's business model influences the market for vaccines. This helps attract new vaccine manufacturers, including an increasing number of suppliers based in emerging markets, increase healthy competition and, as a result, drive vaccine prices down.

Best and the brightest

This is just one example of how Gavi, through task teams & working groups, has provided a space for the best and the brightest in the field of immunisation to find new ways of delivering new vaccines and increasing immunisation rates in developing countries.

Working through Gavi, members of the Vaccine Alliance have developed performance-based approaches to development aid, tested and proved innovative financing mechanisms, and introduced new technologies to boost immunisation coverage.

Six "added values"

This section highlights how the Gavi model has brought "added value" by providing new solutions to six obstacles that have always stood in the way of ensuring life-saving vaccines, which would otherwise take many years to become available in the developing world, reach children in the world's poorest countries:

  1. Getting  immunisation on the agenda in both donor and developing countries;
  2. Finding the type of large-scale funding needed to sustain long-term immunisation programmes;
  3. Aligning immunisation programmes with developing countries' national health plans and systems;
  4. Building health systems that gurantee new vaccines will be delivered to even the remotest villages;
  5. Making expensive new vaccines more affordable for the developing world;
  6. Laying the foundations that will allow governments to continue immunisation programmes long after Gavi support ends.

+ 150 million

By the end of 2013, 11 countries in the African meningitis belt had collectively immunised 153 million people against meningitis A with support from the Vaccine Alliance.

WHO/UNICEF

More facts...

close icon

modal window here